Correlation Between Crinetics Pharmaceuticals and Innovent Biologics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Innovent Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Innovent Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and Innovent Biologics, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Innovent Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Innovent Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Innovent Biologics.

Diversification Opportunities for Crinetics Pharmaceuticals and Innovent Biologics

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between Crinetics and Innovent is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Innovent Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innovent Biologics and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Innovent Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innovent Biologics has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Innovent Biologics go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and Innovent Biologics

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to generate 0.48 times more return on investment than Innovent Biologics. However, Crinetics Pharmaceuticals is 2.1 times less risky than Innovent Biologics. It trades about 0.0 of its potential returns per unit of risk. Innovent Biologics is currently generating about -0.02 per unit of risk. If you would invest  5,715  in Crinetics Pharmaceuticals on August 29, 2024 and sell it today you would lose (38.00) from holding Crinetics Pharmaceuticals or give up 0.66% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Crinetics Pharmaceuticals  vs.  Innovent Biologics

 Performance 
       Timeline  
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Crinetics Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Innovent Biologics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Innovent Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Crinetics Pharmaceuticals and Innovent Biologics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crinetics Pharmaceuticals and Innovent Biologics

The main advantage of trading using opposite Crinetics Pharmaceuticals and Innovent Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Innovent Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innovent Biologics will offset losses from the drop in Innovent Biologics' long position.
The idea behind Crinetics Pharmaceuticals and Innovent Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios